ArticleClinical kidney journal2023
Pseudo-AKI associated with targeted anti-cancer agents-the truth is in the eye of the filtration marker.
Article in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Overview of pseudo-acute kidney injury.Renal failure · 2026Review
- Creatinine-Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib.Clinical pharmacology and therapeutics · 2026Article
- Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology.Cancers · 2026Review
- Pilot Study of Diagnostic Performance of Serum Creatinine/Cystatin C Ratio for Pseudo-AKI.Kidney international reports · 2026Article
- Risk of Acute Kidney Injury Associated With Nephrotoxic Burden in Hospitalized Patients: A Scoping Review.Clinical pharmacology and therapeutics · 2026Article
- Review
- Distinct renal adverse event profiles among CDK4/6 inhibitors: a comparative pharmacovigilance analysis.Frontiers in pharmacology · 2026Article
- Afatinib-associated pseudo-acute kidney injury.Clinical kidney journal · 2025Article
- Knowledge mapping and visualized analysis of research progress in onconephrology: a bibliometric analysis.Renal failure · 2025Article
- Acute kidney injury: pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Kidney Injury in Patient with Non-small-cell Lung Cancer Receiving Tepotinib.Internal medicine (Tokyo, Japan) · 2025Article
- Ten tips for an onco-nephrology clinic.Clinical kidney journal · 2025Review
- Pseudo acute kidney injury in patients receiving CDK4/6 inhibitors.British journal of cancer · 2025Article
- Real-world safety of Tepotinib: Insights from the Food and Drug Administration Adverse Event Reporting System.PloS one · 2025Article
- Editorial: Case reports in nephrology.Frontiers in nephrology · 2025Article
- Serum creatinine, genetic susceptibility, and the risk of osteoporosis and fracture: a prospective cohort study from the UK Biobank.Frontiers in endocrinology · 2025Article
- Effect of Pseudonephrotoxicity on Apparent Acute Kidney Injury Incidence and Severity: A Simulation Study.Clinical journal of the American Society of Nephrology : CJASN · 2024Article
- The impact of VEGF signalling pathway inhibitors and/or immune checkpoint inhibitors on kidney function over time: a single centre retrospective analysis.BJC reports · 2024Article
- Exploring and comparing renal adverse effects between PARP inhibitors based on a real-world analysis of post-marketing surveillance data.Frontiers in medicine · 2024Article
- Case report: A case of pseudo-acute kidney injury due to cyclin-dependent kinase inhibitor.Frontiers in nephrology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Besides true acute kidney injury (AKI), the occurrence of pseudo-AKI has been associated with several targeted agents. To improve the management of cancer patients treated with targeted agents, we need to be aware of this and use diagnostic approaches to differentiate between pseudo-AKI and AKI. In an article by Wijtvliet
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.